MicroRNA-539 Inhibits the Epithelial–Mesenchymal Transition of Esophageal Cancer Cells by Twist-Related Protein 1-Mediated Modulation of Melanoma-Associated Antigen A4

Zhili Cao,*1 Xiang Zheng,†1 Lei Cao,* and Naixin Liang*

*Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P.R. China
†Department of Cardiothoracic Surgery, People’s Hospital of Beijing Daxing District, Beijing, P.R. China

MicroRNAs (miRs) play key roles in cancers, yet the potential molecular mechanisms of miR-539 on esophageal squamous cell carcinoma (ESCC) are not well understood. Utilizing informatics screening, Twist-related protein 1 (TWIST1) was hypothesized to be a possible target gene of miR-539. Since the melanoma-associated antigen (MAGE) A4 is reported to be upregulated by TWIST1, this study aimed to examine the biological functions and mechanism involving TWIST1 and MAGE4 of miR-539 in ESCC. miR-539 mimics or scrambled miRs were transfected into human ESCC TE3 cells to interfere with the expression of miR-539. Then qRT-PCR and Western blot analyses were performed to determine the expression levels of epithelial–mesenchymal transition (EMT)-related factors at mRNA and protein levels. The association between miR-539 and TWIST1 as well as TWIST1 and MAGEA4 was evaluated. The connection of miR-539 and TWIST1–MAGEA4 during the EMT progress of ESCC was also explored. Our data demonstrated that miR-539 inhibited the EMT of TE3 cells by downregulating TWIST1, and TWIST1 was a target of miR-539. Moreover, MAGEA4 was positively correlated with TWIST1, and its knockdown inhibited EMT in TE3 cells. Collectively, miR-539 could inhibit EMT in TE3 cells through TWIST1-mediated regulation of MAGEA4. All these findings suggested that miR-539 may be involved in the progression of ESCC and could be a new therapeutic target for this disease.

Key words: Esophageal cancer; miR-539; TWIST1–MAGEA4; Epithelial–mesenchymal transition (EMT)

INTRODUCTION

Esophageal cancer is one of the most aggressive digestive tract tumors, and esophageal squamous cell carcinoma (ESCC) is one of the most common causes of cancer-associated mortality, which comprises more than 90% of esophageal cancer1–3. In spite of the advances in surgical techniques and perioperative management in recent years, mortality from ESCC has not decreased significantly4,5. Since early ESCC is usually asymptomatic, most ESCC are diagnosed at advanced stages, along with local invasion and lymph node metastasis (LNMs)6,7. Yet the mechanisms contributing to ESCC carcinogenesis are poorly understood.

MicroRNAs (miRs), with a length of 20–24 nucleotides, were widely studied in cell development and differentiation by mediating the posttranscriptional regulation of protein-coding genes8,9. Twist-related protein 1 (TWIST1), a basic helix–loop–helix transcription factor, has been reported to be correlated with multiple cancers, such as renal cell carcinoma, colorectal cancer, prostate cancer, and so on10–12. It is also known as an essential inducer of epithelial–mesenchymal transition (EMT)13. Currently, bioinformatics screening is a potentially cost-effective method to screen the possible target gene of miRs. With the help
of TargetScan (http://www.targetscan.org), TWIST1 was identified as a putative target gene of miR-539. A previous study once claimed that TWIST1 could regulate melanoma-associated antigen (MAGE) A4 expression, suggesting the potential association between TWIST1 and MAGEA4\(^2\). Whether TWIST1 is a target of miR-539 and the possible association between TWIST1 and MAGEA4 in esophageal cancer therefore urgently need to be fully investigated.

In our study, we aimed to identify the specific role of miR-539 in human ESCC cells. The mechanism by which miR-539 regulates EMT as well as the involvements of TWIST1 and MAGEA4 were also investigated. All of our efforts will provide a theoretical basis and new insights for the treatment of ESCC.

**MATERIALS AND METHODS**

**Cell Culture**

Human ESCC TE3 cells, obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan), were grown in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Invitrogen, Carlsbad, CA, USA) in a humidified incubator with 5% CO\(_2\) at 37°C. On the following day the cells were washed twice with PBS and then lysed with 1x sodium dodecyl sulfate (SDS) loading buffer [50 mM Tris-Cl (pH 6.8), 100 mM dithiothreitol (DTT), 2% SDS, 10% glycerol, and 0.1% bromophenol blue]. The protein samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and transfer. Immunoblotting was carried out with primary antibodies against epithelial cadherin (E-cadherin; ab152102), α-smooth muscle actin (α-SMA; ab21027), vimentin (ab188499), MAGEA4 (ab76177), tubulin (as loading control; ab6046) (all from Abcam, Cambridge, UK), caspase-3 (as cleavage marker; Abcam, Cambridge, MA, USA), and -SMA (ab21027) (all from Abcam, Cambridge, UK). The samples were normalized using tubulin expression.

**miR Transfection**

Synthetic miR-539 mimics and scrambled negative control RNA (miR-NC) were purchased from GenePharma (Shanghai, P.R. China). TE3 cells were seeded in six-well plates and cultured at 37°C. On the following day (approximately 70% confluence), cells were transfected with Lipofectamine 2000 reagent (Invitrogen) on the basis of the manufacturer's information. In each well, 100 pmol of miR-539 mimics or miR-NC was used. The expression level of miR-539 was evaluated by quantitative reverse transcription (qRT)-PCR\(^2\). The cells were washed twice with PBS and then lysed with 1x sodium dodecyl sulfate (SDS) loading buffer [50 mM Tris-Cl (pH 6.8), 100 mM dithiothreitol (DTT), 2% SDS, 10% glycerol, and 0.1% bromophenol blue]. The protein samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and transfer. Immunoblotting was carried out with primary antibodies against epithelial cadherin (E-cadherin; ab152102), α-smooth muscle actin (α-SMA; ab21027), vimentin (ab188499), MAGEA4 (ab76177), tubulin (as loading control; ab6046) (all from Abcam, Cambridge, UK), or TWIST1 (MBS9382864; MyBioSource San Diego, CA, USA), respectively. The proteins were detected by enhanced chemiluminescence (ECL Plus; Amersham Pharmacia Biotech, Piscataway, NJ, USA)\(^2\).

**Western Blot Analysis**

The cells were washed twice with PBS and then lysed with 1x sodium dodecyl sulfate (SDS) loading buffer [50 mM Tris-Cl (pH 6.8), 100 mM dithiothreitol (DTT), 2% SDS, 10% glycerol, and 0.1% bromophenol blue]. The protein samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and transfer. Immunoblotting was carried out with primary antibodies against epithelial cadherin (E-cadherin; ab152102), α-smooth muscle actin (α-SMA; ab21027), vimentin (ab188499), MAGEA4 (ab76177), tubulin (as loading control; ab6046) (all from Abcam, Cambridge, UK), or TWIST1 (MBS9382864; MyBioSource San Diego, CA, USA), respectively. The proteins were detected by enhanced chemiluminescence (ECL Plus; Amersham Pharmacia Biotech, Piscataway, NJ, USA)\(^2\).

**Luciferase Activity Assay**

The 3’-untranslated region (3’-UTR) segment of the wt TWIST1 gene, containing the miR-539 binding site, was amplified through PCR and inserted into the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, Madison, WI, USA), which was referred to as TWIST1-wt. Site mutation on the miR-539 binding site in the TWIST1-wt, which was referred to as TWIST1-mut, was obtained using the Directed Mutagenesis System (Invitrogen). TE3 cells were co-transfected with TWIST1-wt or TWIST1-mut and miR-539 or miR-NC using Lipofectamine 2000 reagent. The luciferase activity was analyzed at 48 h posttransfection using the Dual-Luciferase Reporter Assay System (Promega)\(^2\).
RNA Extraction and qRT-PCR

Total RNA was extracted with TRIzol reagent (Invitrogen). For the measurement of miR-539 level, RNA (500 ng) was polyadenylated and reverse transcribed to cDNA using an NCode miRNA First-Strand cDNA Synthesis Kit (Invitrogen). cDNA acted as the template for the real-time PCR using FastStart Universal SYBR Green Master (Roche, Indianapolis, IN, USA). For the detection of mRNA expression, Multiscribe RT Kit and SYBR Green PCR Master Mix (both from Applied Biosystems, Foster City, CA, USA) were utilized for the reverse transcription and quantitative PCR, respectively. Real-time PCR was performed with the Applied Biosystems real-time detection system, and the thermocycling parameters were 95°C for 3 min, followed by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 60 s. Melting curve analysis was performed to confirm the specificity of the PCR products. The replicates were then averaged, and fold induction was determined by a ΔΔCT-based fold change calculation 28. Each sample was run in triplicate and was normalized to U6 short nuclear RNA (snRNA) levels (for miR-539 level) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH; for mRNA levels).

Statistical Analysis

All experiments were repeated three times. The results were presented as the mean ± standard deviation (SD). Statistical analysis was performed using GraphPad Prism 5 software (GraphPad, San Diego, CA, USA). The p values were calculated using the one-way analysis of variance (ANOVA) or two-tailed unpaired t-test. A value of p<0.05 was considered as significantly different.

RESULTS

miR-539 Overexpression Inhibits EMT of TE3 Cells

In this part of the study, miR-539 mimics were transfected into TE3 cells. Then real-time PCR was performed to measure the expression levels of miR-539, and its results showed that miR-539 was markedly upregulated after transfection with the miR-539 mimic compared with the miR-NC group (p<0.001) (Fig. 1A). Transfected TE3
cells were harvested to measure the mRNA and protein expression levels of E-cadherin, α-SMA, and vimentin by real-time PCR (Fig. 1B) and Western blotting (Fig. 1C and D), respectively. The results showed that the overexpression of miR-539 inhibited the expression of α-SMA and vimentin but elevated the expression of E-cadherin in both mRNA (\(p<0.05\) or \(p<0.01\)) and protein (\(p<0.01\) or \(p<0.001\)) expression levels when compared to the miR-NC groups. All the results suggested that overexpression of miR-539 inhibited EMT of TE3 cells.

**miR-539 Directly Regulates the Expression of TWIST1 in TE3 Cells**

The diagram in Figure 2A illustrates the miR-539 base pair with the 3′-UTR of TWIST1. miR-539 mimic or miR-NC and TWIST1-wt or TWIST1-mut were cotransfected into TE3 cells, and then the luciferase activities were measured as shown in Figure 2B. After cotransfection with TWIST1-wt, luciferase activity was significantly reduced by cotransfection with miR-539 mimic compared to that with the miR-NC group (\(p<0.001\)). However, the difference between groups cotransfected with TWIST1-mut was nonsignificant. Then miR-539 mimics or miR-NC was transfected into TE3 cells, followed by Western blot analysis (Fig. 2C and D). The results showed that the protein expression of TWIST1 was observably downregulated by miR-539 overexpression compared with the miR-NC group (\(p<0.001\)). These results indicated that TWIST1 was a target of miR-539.

**miR-539 Overexpression Inhibits EMT of TE3 Cells by Downregulating TWIST1 Expression**

TE3 cells were transfected with different miRNAs or along with plasmids to aberrantly express miR-539 and TWIST1. The cells were harvested and subjected to immunoblot analysis, and the results showed that the miR-539 overexpression-induced alterations of E-cadherin, α-SMA, and vimentin were all reversed by TWIST1 upregulation (\(p<0.05\) or \(p<0.01\)) (Fig. 3A and B). Thus, we concluded that miR-539 inhibited EMT of TE3 cells by downregulating TWIST1 expression.

**miR-539 Regulates MAGEA4 Expression Through TWIST1 in TE3 Cells**

Results of the qRT-PCR in Figure 4A showed that the mRNA level of MAGEA4 was significantly downregulated by TWIST1 knockdown compared with the sh-NC group (\(p<0.001\)). Similarly, the protein expression level of MAGEA4 was also downregulated by TWIST1 knockdown compared with the sh-NC group (\(p<0.01\)) (Fig. 4B and C). Next, cells were stably transfected with pB-TWIST1 or pB-NC and then transiently transfected with...
Figure 3. Connection of miR-539 and TWIST1 on EMT regulation. (A, B) Protein levels of E-cadherin, α-SMA, and vimentin. Tubulin was used as a loading control. Data are presented as mean±SD. *p<0.05; **p<0.01; ***p<0.001. pB-NC, empty pBABE-puro vector; pB-TWIST1, pB-NC carrying full-length wild-type TWIST1 gene.

Figure 4. Effects of miR-539 and TWIST1 on melanoma-associated antigen (MAGE) A4 expression. (A) MAGEA4 mRNA expression after TWIST1 knockdown. (B, C) MAGEA4 protein expression after TWIST1 knockdown. (D, E) Immunoblot analysis of MAGEA4 after cotransfection. Tubulin was used as a loading control. Data are presented as mean±SD. **p<0.01; ***p<0.001. sh-NC, pSicoR vector carrying a nontargeting short hairpin RNAs; sh-TWIST1, pSicoR vector carrying short hairpin RNAs targeting TWIST1.
miR-NC or miR-539 mimics. The cells were harvested and subjected to immunoblot analysis (Fig. 4D and E). The results showed that miR-539 overexpression remarkably decreased the expression of MAGEA4 compared with the miR-NC group (p < 0.001), while the downregulation was reversed by TWIST1 overexpression compared with the miR-539 mimic + pB-NC group (p < 0.001), indicating that miR-539 could regulate MAGEA4 expression through TWIST1.

MAGEA4 Positively Regulates EMT in TE3 Cells

First, TE3 cells were transfected with sh-MAGEA4, and the results in Figure 5A demonstrated that the protein expression of MAGEA4 was obviously downregulated by sh-MAGEA4 compared with the sh-NC group. Then the transfected cells were harvested and subjected to immunoblot analysis, by which α-SMA and vimentin were found to be downregulated, while E-cadherin was upregulated by MAGEA4 knockdown compared with the sh-NC group (Fig. 5B). Next, cells were stably transfected with pB-MAGEA4 or pB-NC, along with transient transfection with miR-539 mimic or miR-NC. The immunoblot analysis of transfected cells in Figure 5C and D revealed that miR-539 overexpression obviously upregulated E-cadherin (p < 0.01) but downregulated α-SMA (p < 0.05) and vimentin (p < 0.01) when compared to the miR-NC group. However, the alterations induced by miR-539 overexpression could be reversed by MAGEA4 overexpression compared with the miR-539 mimic + pB-NC group (p < 0.01 or p < 0.001). Collectively, all the results suggested that MAGEA4 positively regulates EMT in TE3 cells, and miR-539 overexpression inhibited EMT through downregulating MAGEA4.

DISCUSSION

The incidence of esophageal cancer has increased rapidly in the past decades and caused high rates of mortality for the poor prognosis. ESCC is the main histological type of esophageal cancer with high mortality around the world, which is highly invasive, rapidly metastatic, and results in a poor postoperative quality of life. In our study, we focused on the effect of miR-539 on ESCC cells and interestingly identified that miR-539 functioned as a tumor suppressor and inhibited EMT by regulating TWIST1–MAGEA4. Subsequent experiments illustrated that TWIST1 was a target of miR-539, and miR-539 functioned through downregulation of TWIST1. Next, miR-539 was demonstrated to regulate MAGEA4 expression, mediated by TWIST1. Finally, MAGEA4 knockdown could repress EMT, and miR-539 functioned through TWIST1-mediated regulation of MAGEA4.

Figure 5. Effect of MAGEA4 on EMT of esophageal cancer cells. (A) MAGEA4 protein expression after transfection with sh-NC or sh-MAGEA4. (B) Expression of E-cadherin, α-SMA, and vimentin after MAGEA4 knockdown. (C, D) Detection of E-cadherin, α-SMA, and vimentin expression in protein levels by Western blot assay. Tubulin was used as a loading control. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. sh-MAGEA4, pSicoR vector carrying short hairpin RNAs targeting MAGEA4; pB-MAGEA4, pB-NC carrying full-length wild-type MAGEA4 gene.
The development and progress of ESCC are influenced by many factors, multiple genes, and progress of many stages. The study of Xue et al. confirmed that ESCC patients with higher miR-483-5p levels had a significantly shorter overall survival time, suggesting that miR-483-5p might be a tumor promoter of ESCC. However, the functional role of miR-539 in ESCC remains unclear. E-cadherin is a major hemophilic cell–cell adhesion molecule, which inhibits cell migration. EMT was evaluated as the loss of E-cadherin and the increase in mesenchymal markers, such as α-SMA and vimentin. In our study, we observed that miR-539 could inhibit EMT in TE3 cells, showing marked upregulation of E-cadherin and down-regulation of α-SMA and vimentin, which was consistent with previous literature.

miRs normally participate in physiological activities through the posttranscriptional modulation of target genes. According to the bioinformatics screen with TargetScan, TWIST1 was a potential target gene of miR-539. In our study, the results of the luciferase activity assay strongly validated that TWIST1 was a direct target of miR-539. The following experiments that measured the expression level of TWIST1 in TE3 cells with aberrant expression of miR-539 demonstrated that TWIST1 was negatively correlated with the miR-539 level. In addition, the Western blotting results of cotransfected cells implied that the miR-539 overexpression repressed EMT through downregulating TWIST1, as the TWIST1 overexpression could reverse the changes induced by miR-539 overexpression. To further explore the underlying mechanism of the miR-539-associated modulations, the possible responsive factor of TWIST1 was studied. MAGEA4 has been reported to be upregulated in different types of cancer including ESCC, and the upregulation of MAGEA4 is expected to be a prognostic marker for patients with ESCC. On account of a previous study, demonstrating that MAGEA4 could be upregulated by TWIST1, we further explored the potential association between TWIST1 and MAGEA4 in TE3 cells. In our study, MAGEA4 was positively correlated with TWIST1 expression, consistent with the results described above. Additionally, MAGEA4 expression was decreased by miR-539 overexpression. We hypothesized that the downregulation of TWIST1 induced by miR-539 overexpression might be the possible reason. The following experiments showed that TWIST1 overexpression could reverse the miR-539-induced alteration of MAGEA4, consolidating our hypothesis. Thus, we concluded that TWIST1 acted as a mediator to connect miR-539 to MAGEA4. Further studies also proved that MAGEA4 knockdown could inhibit EMT, and miR-539 overexpression inhibited EMT through TWIST1-mediated downregulation of MAGEA4.

Taken together, our results collectively showed the roles of miR-539 in ESCC, which are closely correlated with TWIST1–MAGEA4, suggesting that miR-539 can serve as a potential therapeutic target for ESCC.

REFERENCES
1. Xue L, Nan J, Dong L, Zhang C, Li H, Na R, He H, Wang Y. Upregulated miR-483-5p expression as a prognostic biomarker for esophageal squamous cell carcinoma. Cancer Biomark. 2017;19(2):193–7.
2. Huang Z, Zhang L, Zhu D, Shan X, Zhou X, Qi LW, Wu L, Zhu J, Cheng W, Zhang H, Chen Y, Zhu W, Wang T, Liu P. A novel serum microRNA signature to screen esophageal squamous cell carcinoma. Cancer Med. 2017;6(1):109–19.
3. Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma. J Thorac Dis. 2017;9(1):200–4.
4. Mu JW, Gao SG, Xue Q, Mao YS, Wang DL, Zhao J, Gao YS, Huang JF, He J. The impact of operative approaches on outcomes of middle and lower third esophageal squamous cell carcinoma. J Thorac Dis. 2016;8(12):3588–95.
5. Huang Y, Wang H, Luo G, Zhang Y, Wang L, Li K. A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. Int J Surg. 2017;38:41–7.
6. Sugase T, Takahashi T. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice. Int J Cancer 2017;140(11):2608–21.
7. Kituchi T, Yasui K, Gen Y, Dohi O, Iwai N, Tomie A, Yamada N, Terasaki K, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Naito Y, Zen Y, Itoh Y. Loss of PAR-3 protein expression is associated with invasion, lymph node metastasis, and poor survival in esophageal squamous cell carcinoma. Hum Pathol. 2017;62:134–40.
8. Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negri M. MicroRNAs in liver cancer: A model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22(1):46–57.
9. Ribeiro J, Sousa H. MicroRNAs as biomarkers of cervical cancer development: A literature review on miR-125b and miR-34a. Mol Biol Rep. 2014;41(3):1525–31.
10. Yi R, Li Y, Wang FL, Miao G, Qi RM, Zhao YY. MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol. 2016;8(4):330–40.
11. Fang Z, Zhiping Y, Minjun C, Yinsheng X, Jintao L, Xuebin C, Zhi G, Jing X, Shaomei Z, Zhixiang Z. MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. Cancer Lett. 2014;342(1):121–9.
12. Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 2013;104(1):48–54.
13. Gu L, Sun W. MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1. Biochem Biophys Res Commun. 2015;464(4):1128–33.
14. Zhang H, Li S, Xiong Y, Qiao B, Zhang Z, Yong X. miR-539 inhibits prostate cancer progression by directly targeting SPAG5. J Exp Clin Cancer Res. 2016;35(1):60.
15. Gomez-Gomez Y, Organista-Nava J, Gariglio P. Deregu- lation of the miRNAs expression in cervical cancer: Human papillomavirus implications. Biomed Res Int. 2013;2013: 407052.

16. Strubberg AM, Madison BB. MicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications. Dis Model Mech. 2017;10(3):197–214.

17. Yoshino H, Yonemori M, Miyamoto K, Tatarano S, Kofuji S, Nohata N, Nakagawa M, Enokida H. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigen- esis through revival of TWIST1 in renal cell carcinoma. Oncotarget 2017;8(13):20881–94.

18. Chuang HY, Jiang JK, Yang MH, Wang HW, Li MC, Tsai CY, Jhang YY, Huang JC. Aminopeptidase A initi- ates tumorigenesis and enhances tumor cell stenness via TWIST1 upregulation in colorectal cancer. Oncotarget 2017;8(13):21266–80.

19. Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Eto M. Protein kinase C regulates Twist1 expression via NF-kappaB in prostate cancer. Endocr Relat Cancer 2017;24(4):171–80.

20. Lee KW, Yeo SY, Sung CO, Kim SH. Twist1 is a key regulator of cancer-associated fibroblasts. Cancer Res. 2015;75(1):73.

21. Forghanifard MM, Rad A, Farschian M, Khaleghizadeh M, Moghlin M, Abbazadehgan MR. TWIST1 up-regulates the MAGEA4 oncogene. Mol Carcinog. 2017;56(3):877–85.

22. Chen XY, He QY, Guo MZ. XAF1 is frequently methy- lated in human esophageal cancer. World J Gastroenterol. 2012;18(22):2844–9.

23. Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 2014;124(1):84–95.

24. Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW, Cho EJ, Han JW. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 2015;6: e1964.

25. Satsyer L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther. 2002;9(17): 1155–62.

26. Jin Y, Leung WK, Sung JJ, Wu JR. p53-independent pRB degradation contributes to a drug-induced apoptosis in AGS cells. Cell Res. 2005;15(9):695–703.

27. Cao LL, Xie JW, Lin Y, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY, Huang CM. miR-183 inhibits invasion of gastric cancer by targeting Ezrin. Int J Clin Exp Pathol. 2014;7(9):5582–94.

28. Motino O, Frances DE, Mayoral R. Regulation of microRNA 183 by cyclooxygenase 2 in liver is DEAD- box helicase p68 (DDX5) dependent: Role in insulin sig- naling. Mol Cell Biol. 2015;35(14):2554–67.

29. Iams WT, Villaflor VM. Neoadjuvant treatment for locally invasive esophageal cancer. World J Surg. 2017;41(7):1719–25.

30. Sun X, Zhao D, Liu Y, Liu Y, Yuan Z, Wang J, Xue F. The long-term spatial-temporal trends and burden of esophageal cancer in one high-risk area: A population-registered study in Feicheng, China. PLoS One 2017;12(3):e0173211.

31. Meng X, Chen X, Lu P, Ma W, Yue D, Song L, Fan Q. miR-202 promotes cell apoptosis in esophageal squamous cell carcinoma by targeting HSF2. Oncol Res. 2017;25(2): 215–23.

32. Mei LL, Qiu YT, Zhang B, Shi ZZ. MicroRNAs in esoph- ageal squamous cell carcinoma: Potential biomarkers and therapeutic targets. Cancer Biomark. 2017;19(1):1–9.

33. Chen CH, Lu HI, Wang YM, Chen YH, Lo CM, Huang WT, Li SH. Areca nut is associated with younger age of diagnosis, poor chemoradiotherapy response, and shorter overall survival in esophageal squamous cell carcinoma. PLoS One 2017;12(2):e0172752.

34. Danfeng, Chen, ShannChing, Prasad, Mohit, He, Li, Wang, Xiaobo. Mechanical feedback through E-cadherin pro- motes direction sensing during collective cell migration. Cell 2014;157(5):1146–59.

35. Watanabe O, Tsuji T, Kikuchi R, Itoh M, Nakamura H, Aoshiba K. Little evidence for epithelial-mesenchymal transition in a murine model of airway fibrosis induced by repeated naphthalene exposure. Exp Toxicol Pathol. 2016;68(9):517–20.

36. Hui J, Wang W. MicroRNA-539 suppresses osteosarcoma cell invasion and migration in vitro and targeting matrix metalloproteinase-8. Int J Clin Exp Pathol. 2015;8(7): 807–82.

37. Tang WW, Liu ZH, Yang TX, Wang HJ, Cao XF. Upregulation of MAGEA4 correlates with poor prognosis in patients with early stage of esophageal squamous cell car- cinoma. Onco Target Ther. 2016;9(1):4289–93.